Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
24 October 2022 - 11:00PM
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage
biotechnology company developing innovative, investigational
therapeutics targeting hepatitis B virus (HBV) and other viral
diseases, today announced that clinical and preclinical data from
its virology portfolio will be featured in four poster
presentations, including two late breaker presentations, at the
upcoming American Association for the Study of Liver Diseases
(AASLD), The Liver Meeting®, taking place November 4-8, 2022, in
Washington, DC.
The presentations will include preclinical data supporting the
advancement of the company’s next-generation core inhibitor
candidate, ABI-4334 (4334), into clinical development for the
treatment of hepatitis B virus (HBV), with a Phase 1a trial
expected to start in H2 2022. Data highlighting the preclinical
characterization of Assembly Bio’s novel small molecule viral entry
inhibitor for HBV and hepatitis delta virus (HDV) will also be
presented. Additionally, two poster presentations accepted as
late-breaking abstracts will focus on Assembly Bio’s interferon-α
receptor (IFNAR) agonist research program and the ongoing Phase 2
study evaluating first-generation core inhibitor vebicorvir in
combination with Arbutus Biopharma’s AB-729 in HBV.
“We look forward to presenting data at AASLD’s The Liver Meeting
that demonstrate the promise of our pipeline, strength of our
science and breadth of our expanded research efforts,” said William
Delaney, PhD, chief scientific officer of Assembly Bio. “Notably,
we will highlight preclinical data exploring the activity of our
highly potent next-generation core inhibitor 4334 against the
formation of cccDNA, the HBV viral reservoir. We will also present
for the first time preclinical data from our oral viral entry
inhibitor research program introduced earlier this year, which
builds upon our core inhibitor portfolio with a complementary
mechanism against HBV while also extending our research focus to
HDV.”
Details of the poster presentations are as follows; presentation
details on the two additional late-breaking posters will be
available closer to the meeting:
- Poster
Presentation #1119: ABI-4334, a novel hepatitis B virus
core inhibitor, accelerates capsid assembly and inhibits cccDNA
formation via multiple pathways First Author:
Nuruddin Unchwaniwala, PhD, Assembly BioSession:
Posters Date and Time: Friday, November 4, 2022,
12:00 p.m. ET
- Poster Presentation #1132: Preclinical
characterization of a novel class of highly potent small molecule
hepatitis B and D virus entry inhibitors First
Author: Heidi Contreras, PhD, Assembly
BioSession: PostersDate and Time:
Friday, November 4, 2022, 12:00 p.m. ET
AASLD Presentations and
PostersPresentations and posters are expected to be made
available online to conference registrants through The Liver
Meeting Digital Experience™ at
https://www.aasld.org/the-liver-meeting/digital-experience within
72 hours of presentation. The full posters will be available online
at the “Events & Presentations” page in the “Investors”
section of Assembly's website
at www.assemblybio.com.
About Assembly BiosciencesAssembly Bio is
a clinical-stage biotechnology company pioneering the development
of novel therapeutics for serious viral diseases. Assembly Bio is
advancing a leading portfolio of more potent, next-generation core
inhibitor drug candidates that aim to break the complex viral
replication cycle of hepatitis B virus (HBV) to achieve finite and
potentially curative therapies for the 296 million people living
with HBV worldwide. The company’s research pipeline includes
differentiated antiviral approaches against HBV/hepatitis delta
virus and herpesviruses. For more information,
visit assemblybio.com.
Forward-Looking StatementsThe information in
this press release contains forward-looking statements that are
subject to certain risks and uncertainties that could cause actual
results to materially differ. These risks and uncertainties
include: Assembly Bio’s ability to successfully execute its
previously announced reprioritization and restructuring activities,
including the CEO transition; potential adverse legal,
reputational, operational and financial effects on Assembly Bio
resulting from the reprioritization and restructuring activities;
Assembly Bio’s ability to initiate and complete clinical studies
involving its therapeutic product candidates, including studies
contemplated by Assembly Bio’s collaboration agreements, in the
currently anticipated timeframes; safety and efficacy data from
clinical studies may not warrant further development of Assembly
Bio’s product candidates; clinical and nonclinical data presented
at conferences may not differentiate Assembly Bio’s product
candidates from other companies’ candidates; results of nonclinical
studies may not be representative of disease behavior in a clinical
setting and may not be predictive of the outcomes of clinical
studies; continued development and commercialization of ABI-H3733,
if successful, in the China territory will be dependent on, and
subject to, Assembly Bio’s collaboration agreement governing this
activity in the China territory; Assembly Bio’s ability to maintain
financial resources necessary to continue its clinical studies and
fund business operations; any impact that the COVID-19 pandemic may
have on Assembly Bio’s business and operations, including
initiation, enrollment and continuation of its clinical studies or
timing of discussions with regulatory authorities; and other risks
identified from time to time in Assembly Bio’s reports filed with
the U.S. Securities and Exchange Commission (the SEC). You are
urged to consider statements that include the words may, will,
would, could, should, might, believes, hopes, estimates, projects,
potential, expects, plans, anticipates, intends, continues,
forecast, designed, goal or the negative of those words or other
comparable words to be uncertain and forward-looking. Assembly Bio
intends such forward-looking statements to be covered by the safe
harbor provisions contained in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. More information about Assembly Bio’s risks and
uncertainties are more fully detailed under the heading “Risk
Factors” in Assembly Bio’s filings with the SEC, including its most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and Current Reports on Form 8-K. Except as required by law,
Assembly Bio assumes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts
Investor and Corporate:Shannon RyanSVP,
Investor Relations, Corporate Affairs and Alliance Management(415)
738-2992sryan@assemblybio.com
Media:Sam Brown Inc.Hannah Hurdle(805)
338-4752ASMBMedia@sambrown.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2023 to Apr 2024